FDA 483 - Suzhou Homesun Pharmaceutical Co., Ltd. - April 12, 2019
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Suzhou Homesun Pharmaceutical Co. Ltd. in Jiangsu, P.R. China, revealed numerous deficiencies in their manufacturing of active pharmaceutical ingredients (APIs). The firm was cited for poor facility and equipment maintenance, inadequate material identification and storage, and significant gaps in documentation for critical operations, laboratory testing, and quality reviews. These issues indicate a lack of adherence to good manufacturing practices and robust quality control systems.
ID · e202478c-cf07-4bd1-82b7-092d0ef1ce64